FDA Ends Mandatory Animal Testing for Cancer Therapeutics Effective June 2026

The U.S. Food and Drug Administration (FDA) has officially shifted its regulatory framework to move away from mandatory animal testing for cancer therapeutics as of June 2026. This policy change coincides with a broader period of transition for the agency, which is currently managing new vaccine protocols and addressing public discourse regarding the potential politicization of its regulatory processes.

Biopharmaceutical companies are currently adjusting their development pipelines to align with these updated testing requirements. While the agency implements these changes, industry stakeholders and observers are also monitoring ongoing debates surrounding the use of priority review vouchers (PRVs). These discussions reflect a wider trend of scrutiny regarding the agency’s operational priorities and the evolving standards for drug approval as the industry enters the second half of the year.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI